Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer

摘要: Purpose: The homeodomain transcription factor CDX2 is a relatively specific immunohistochemical marker for gastrointestinal carcinoma. However, no study has comprehensively examined the relationship between expression in colon cancer and clinical, pathologic, prognostic, molecular features, including microsatellite instability CpG island methylator phenotype (CIMP). Experimental Design : Utilizing 621 colorectal cancers with clinical outcome data, loss was detected 183 (29%) tumors by immunohistochemistry. Results In multivariate logistic regression analysis, associated female gender [odds ratio (OR), 3.32; P = 0.0003), high tumor grade (OR, 2.69; 0.0085), stage IV disease 2.03; 0.019), inversely LINE-1 hypomethylation (for 30% decline; OR, 0.33; 0.0031), p53 0.55; 0.011), β-catenin activation 0.60; 0.037), but not body mass index, location, instability, BRAF, KRAS, PIK3CA, p21, or cyclooxygenase-2. independently patient survival. prognostic effect of seemed to differ according family history ( interaction 0.0094). overall mortality (multivariate hazard ratio, 2.40; 95% CI, 1.28-4.51) among patients cancer; such association present 0.97; 0.66-1.41) without cancer. Conclusions gender, CIMP-high, high-level methylation, grade, advanced stage. may be poor prognosis